Search Results
Your search for ,wAS matches 27593 pages
Showing 24251 - 24300Genetic Testing in Breast Cancer Offers Much Information but Poses Challenges in Interpretation
For breast cancer patients with robust family histories, medical oncologists should be testing not only for BRCA1/2 mutations, but also for large duplications and deletions as well as for PALB2 mutations. “These [findings] have proven utility in testing breast cancer patients,” said Louise E....
Novel Combination Increases Progression-Free Survival in CLL Patients Who Are Not Candidates for Fludarabine
In the phase III COMPLEMENT 1 trial reported in The Lancet, Peter Hillmen, MB, ChB, of St. James’s University Hospital, Leeds, and colleagues found that the addition of the anti-CD20 antibody ofatumumab (Arzerra) to chlorambucil (Leukeran) increased progression-free survival among patients with...
Brentuximab Vedotin for Consolidation Therapy in High-Risk Hodgkin Lymphoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On August 17, 2015, brentuximab vedotin (Adcetris) was approved...
Suicide After Cancer: Understanding the Challenges Across the Treatment Trajectory
Suicidal thoughts and impulses are among the most challenging symptoms in patients with cancer, and they may occur both during and after treatment. It has long been known that a cancer diagnosis carries an increased risk for suicide, but the problem is not widely addressed. Suicide is one of the...
International Psycho-Oncology Society and American Psychosocial Oncology Society Meet to Foster Psychosocial Oncology Worldwide
The International Psycho-Oncology Society (IPOS) has partnered with the American Psychosocial Oncology Society (APOS) for the 17th World Congress of Psycho-Oncology, held in late July 2015 in Washington, DC. Its theme, “From National to Global: Implementing the Standard of Psychosocial Care in...
IPOS Announces 2015 Award Winners at the World Congress of Psycho-Oncology
The International Psycho-Oncology Society (IPOS) announced four award winners at the 2015 World Congress of Psycho-Oncology, held July 28 to August 1 in Washington, DC. Arthur M. Sutherland Award: William H. Redd, PhD Dr. Redd is Professor of Oncological Sciences at the Mount Sinai Hospital. He is...
HPV16 DNA in Post-Treatment Oral Rinses Signals Poor Prognosis in Oropharyngeal Cancer
Detectable oral HPV16 DNA in oral rinses post treatment for oropharyngeal cancer appears to be a harbinger of poor prognosis and can predict recurrence. Oral HPV16 DNA rinses are a potential tool for long-term tumor surveillance, according to a study selected for the Best of ASCO® 2015.1 “The goal ...
Role of Surgery and Adjuvant Radiotherapy in the Treatment of Breast Cancer Explored
Two separate retrospective studies have further refined our understanding of the respective contributions of surgery and radiotherapy in the treatment of breast cancer. However, these studies are not definitive, and “gold standard” trials are needed to arrive at definitive recommendations. Both...
Optimal Timing of Hormonal Therapy for Biochemically Recurrent Prostate Cancer Remains Unclear
There is no consensus as to whether it is better to treat immediately or to delay androgen-deprivation therapy in patients with a rising prostate-specific antigen (PSA) level (“biochemical relapse”) after curative therapy for prostate cancer. A phase III study, selected for the Best of ASCO® 2015,...
Secondary Prevention in Metastatic Colorectal Cancer: Benefits of Vitamin D and Aspirin Explored
Two low-cost, low-tech options may lead to a survival benefit in metastatic colorectal cancer, according to separate retrospective studies selected for the Best of ASCO® 2015. The first study suggested that vitamin D supplementation is worthy of investigation in this regard,1 and the second study...
Colorectal Liver Metastases: Thumbs Up for Radiofrequency Ablation, Jury Still Out for Selective Internal Radiotherapy
Two “firsts” in studies of colorectal liver metastases were highlighted at the 2015 ASCO Annual Meeting: the first prospective randomized trial to evaluate radiofrequency ablation plus chemotherapy1 and the first large randomized phase III trial to study liver-directed selective internal radiation...
Indolent Lymphoma: A More Complex Malignancy Than Once Thought
With a growing number of options for follicular lymphoma, clinicians may wonder whether there is one best regimen. James O. Armitage, MD, FACP, FRCP, Professor of Medicine at the University of Nebraska, Omaha—and Editor-in-Chief of The ASCO Post—tackled this question and offered recommendations at...
Positioning Targeted and Immunotherapy-Based Approaches in Lung Cancer
With immunotherapy changing the face of lung cancer, is there still a place for targeted therapy? Two experts from Emory University debated this issue at the 2015 Debates and Didactics in Hematology and Oncology Conference held in Sea Island, Georgia. Fadlo Khuri, MD, was recently named President...
Charting a New Course: From Clinical Investigator to University President
What first intrigued Fadlo R. Khuri, MD, FACP, about the prospect of becoming the 16th President of the American University of Beirut (AUB) in Lebanon was the chance to give back to an institution and a country that had given him so much. Born in Boston, Massachusetts, in 1963, Dr. Khuri was raised ...
Elotuzumab Ushers in a New Era in Myeloma Therapy
The long wait for monoclonal antibodies for the treatment of multiple myeloma is over. In the landmark ELOQUENT-2 study, reviewed in this issue of The ASCO Post, Lonial and colleagues convincingly demonstrate the effectiveness of elotuzumab, a monoclonal antibody directed against SLAMF7, in the...
Adding Elotuzumab to Lenalidomide Plus Dexamethasone Improves Progression-Free Survival in Refractory Multiple Myeloma
In an interim analysis of the phase III ELOQUENT-2 trial reported in The New England Journal of Medicine, Sagar Lonial, MD, of Emory University School of Medicine, Meletios Dimopoulos, MD, of National and Kapodistrian University of Athens, and colleagues found that the addition of elotuzumab to...
Azacitidine Increased Median Overall Survival Among Patients Aged 65 and Older With > 30% Blasts
A multicenter, randomized, open-label, phase III trial among the difficult-to-treat population of patients aged aged 65 and older with acute myeloid leukemia (AML) with > 30% bone marrow blasts “showed that azacitidine was associated with a clinically meaningful improvement” in median overall...
‘Encouraging Results’ With Newer EGFR TKIs in Patients With NSCLC Who Progressed After Prior EGFR TKI Therapy
Two studies of third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors among patients with non–small cell lung cancer (NSCLC) who had progressive disease following treatment with a first-generation EGFR tyrosine kinase inhibitor “show encouraging results,” according to...
My Positive Attitude Is Keeping Me Alive
Until I was diagnosed with stage III renal cell carcinoma in early 2008, I had no firsthand experience with cancer. To my knowledge, there is no history of cancer in my immediate family, and despite a smoking habit I picked up when I was young, I had been in relatively good health in the 56 years...
Let It Be Hard
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Jeffrey S. Weber, MD, PhD, Joins NYU Langone and Perlmutter Cancer Center
Jeffrey S. Weber, MD, PhD, an expert in immunotherapy and melanoma, will join the senior faculty of NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center. Dr. Weber will serve as Deputy Director of the Perlmutter Cancer Center and Codirector of its Melanoma Program and will...
Internationally Acclaimed Cancer Researcher, Gianni Bonadonna, MD, Dies at 81
Gianni Bonadonna, MD, was considered the “Father of Italian Oncology,” but his scientific contributions to the field and his generous collegial spirit extended far beyond the shores of his native land. Dr. Bonadonna was at the forefront in the battle to convince the surgical establishment that...
In Search of a Good Ending for a Life Well Lived
BOOKMARK Title: The Conversation: A Revolutionary Plan for End-of-life CareAuthor: Angelo E. Volandes, MDPublisher: BloomsburyPublication date: January 13, 2015Price: $26.00; hardcover, 240 pages A quick Google search on books about end-of-life care will yield pages of hits on the subject. The...
Microbes by the Trillions
BOOKMARK Title: 10% Human: How Your Body’s Microbes Hold the Key to Health and HappinessAuthor: Alanna CollenPublisher: Harper CollinsPublication date: April 27, 2015Price: $39.99; hardcover, 400 pages "As I walked back through the forest that night in the summer of 2005, with twenty bats in...
ASCO 2015: Geriatric Oncology Highlights
The theme of the 2015 ASCO Annual Meeting, Illumination and Innovation, is especially appropriate as we consider the field of geriatric oncology. For too long, the elderly cancer patient has remained in the dark regarding treatment planning, clinical trial enrollment, and shared decision-making....
MD Anderson Names Valerae O. Lewis, MD, Chair of Orthopaedic Oncology
Valerae O. Lewis, MD, has been named Chair of Orthopaedic Oncology at The University of Texas MD Anderson Cancer Center. Dr. Lewis has been a faculty member at MD Anderson for 15 years, serving in a variety of roles. The unit she will lead, the Department of Orthopaedic Oncology, is a new...
Statin Use at Start of Androgen-Deprivation Therapy Increases Time to Progression During Treatment of Prostate Cancer
Statin use has been associated with improved outcomes in prostate cancer. In a study reported in JAMA Oncology, Lauren C. Harshman, MD, of Dana-Farber Cancer Institute, Boston, and colleagues found that statin use at the time of the initiation of androgen-deprivation therapy was associated with...
Updated Analysis of Menopausal Hormone Therapy and Breast Cancer Risk
As reviewed in this issue of The ASCO Post, Chlebowski and colleagues1 reported differing patterns of breast cancer risk during or after hormonal therapy with estrogen plus progestin2 or estrogen alone,3 in an analysis of two Women’s Health Initiative (WHI) trials. This recent update on risk...
Differing Patterns of Breast Cancer Risk After Hormone Therapy With Estrogen Plus Progestin or Estrogen Alone
In an analysis of Women’s Health Initiative trials reported in JAMA Oncology, Rowan T. Chlebowski, MD, PhD, of Harbor-UCLA Medical Center, and colleagues found differing patterns of breast cancer risk among women receiving menopausal hormone therapy with estrogen plus progestin or estrogen alone.1...
Immune Checkpoint Inhibitor Nivolumab Is Active in Patients With Heavily Pretreated Advanced Non–Small Cell Lung Cancer
In a phase I cohort expansion trial reported in the Journal of Clinical Oncology, Scott N. Gettinger, MD, of Yale Cancer Center, New Haven, Connecticut, and colleagues found that monotherapy with the anti–programmed cell death protein 1 (PD-1) checkpoint inhibitor antibody nivolumab (Opdivo)...
NCI Awards Huntsman Cancer Institute, University of New Mexico Cancer Center Comprehensive Cancer Center Designations
The National Cancer Institute (NCI) recently awarded Huntsman Cancer Institute (HCI) at the University of Utah and The UNM Cancer Center (UNMCC) at the University of New Mexico Comprehensive Cancer Center status. An NCI-Designated Comprehensive Cancer Center must demonstrate depth and breadth of...
FDA Accepts for Priority Review the Biologics License Application for Elotuzumab for the Treatment of Relapsed Multiple Myeloma
Bristol-Myers Squibb and AbbVie recently announced that the U.S. Food and Drug Administration has accepted for priority review the Biologics License Application for elotuzumab, an investigational signaling lymphocyte activation molecule (SLAMF7)-directed immunostimulatory antibody, for the...
FDA Grants Regular Approval to Brentuximab Vedotin in High-Risk Classical Hodgkin Lymphoma
The U.S. Food and Drug Administration has approved brentuximab vedotin (Adcetris) as post–autologous hematopoietic stem cell transplantation consolidation treatment for patients with classical Hodgkin lymphoma at high risk of relapse or progression, Seattle Genetics has announced. The approval is...
Conquer Cancer Foundation Donor Spotlight: Fibrolamellar Cancer Foundation
When Tucker Davis was diagnosed with fibrolamellar hepatocellular carcinoma (FL-HCC) in 2008, there was very little information about this very rare cancer and, as Tucker would soon discover, even fewer treatment options available. An annoying cough and sharp pain radiating down his back leg...
Barbara Pro, MD, Joins the Lurie Cancer Center
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University announced the addition of medical oncologist Barbara Pro, MD. A leader in the research and treatment of lymphomas, Dr. Pro joined the Lurie Cancer Center in September 2015. She has been appointed Professor of Medicine in...
FDA Approves Rolapitant for Prevention of Chemotherapy-Induced Nausea and Vomiting
The U.S. Food and Drug Administration (FDA) approved rolapitant (Varubi) to prevent delayed-phase chemotherapy-induced nausea and vomiting. Rolapitant is approved in adults in combination with other antiemetic agents that prevent nausea and vomiting associated with initial and repeat courses of...
Carl H. June, MD, Awarded the 2015 Watanabe Prize
Carl H. June, MD, an internationally recognized leader in the growing field of immunotherapy, was awarded the Watanabe Prize at the 7th Annual Meeting of the Indiana Clinical and Translational Sciences Institute (CTSI) on September 11 on the campus of Indiana University–Purdue University...
Texas Center for Proton Therapy Names Chang Chang, PhD, Director of Physics
Chang Chang, PhD, a leader in proton therapy medical physics, has been named Director of Physics at Texas Center for Proton Therapy. Previously, as Senior Medical Physicist at ProCure Proton Therapy Center in Somerset, New Jersey, Dr. Chang was involved in the commissioning of new proton technology ...
2015 ASTRO Gold Medal Recipients Announced
The American Society for Radiation Oncology (ASTRO) has chosen three radiation oncology physicians and researchers to receive the 2015 ASTRO Gold Medal: Carl R. Bogardus, Jr, MD, FASTRO; Carl M. Mansfield, MD, ScD (Hon), FASTRO; and James B. Mitchell, PhD, FASTRO. Drs. Bogardus, Mansfield, and...
Tari King, MD, Named Chief of Breast Surgical Services at Dana-Farber/Brigham and Women’s Cancer Center
Tari King, MD, has been appointed Chief of Breast Surgery at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC). Dr. King will hold appointments at Brigham and Women’s Hospital, Faulkner Hospital, and Dana-Farber Cancer Institute. Dr. King will oversee breast surgery in the DF/BWCC, which...
One Doctor’s Road to Palliative Care Services in the Inner City
St. Barnabas Hospital is located in the heart of Bronx, New York, and as such, it has a culturally diverse, largely poor, patient population. The backbone of successful palliative care services is the doctor-patient communication bonding process. However, many of the patients with late-stage cancer ...
James P. Allison, PhD, Wins Clinical Medical Research Lasker-DeBakey Award
James P. Allison, PhD, Chair of Immunology at The University of Texas MD Anderson Cancer Center, has been named the 2015 winner of the Lasker-DeBakey Clinical Medical Research Award from the Albert and Mary Lasker Foundation. The Lasker awards, in their 70th year, honor major achievements in basic...
Bevacizumab Plus Standard Chemotherapy Improves Survival in Mesothelioma
The standard of care for malignant pleural mesothelioma may be poised for change, judging by results from a study by the French Cooperative Thoracic Intergroup. The addition of bevacizumab (Avastin) in the first-line setting to the current standard of care, pemetrexed (Alimta)/cisplatin, improved...
Radiation Oncology Looks to Collaboration for Big Data Systems
Radiation oncologists dream of a day when, faced with a new patient sitting in their office, they can quickly consult a computer database offering specific treatment recommendations based on accurate, freshly updated data from millions of previously treated patients with cancer. To hasten that day, ...
Rolapitant for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On September 2, 2015, rolapitant (Varubi) was approved for use in...
HPV-Positive Head and Neck Cancer: When Can Chemotherapy Be Omitted?
Are there patients with locally advanced squamous cell carcinoma of the head and neck associated with human papillomavirus (HPV) for whom chemotherapy can be omitted? Experts debated this question at the 2015 Debates and Didactics in Hematology and Oncology Conference in Sea Island, Georgia,...
Yale Cancer Center Receives $11 Million SPORE Grant for Lung Cancer Research
The National Cancer Institute (NCI) recently awarded Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven a Specialized Program of Research Excellence, or SPORE, grant worth $11 million. The Yale SPORE will launch a new research program in non–small cell lung cancer. The new research...
Mantle Cell Lymphoma: Is Transplantation Still Necessary?
Autologous stem cell transplantation has played a critical role in the treatment of mantle cell lymphoma, but in the age of novel treatments, is it always warranted? Two experts in the field explored the question at the 2015 Debates and Didactics in Hematology and Oncology Conference sponsored by...
About the Summit
The research summit was part of the ASCO Obesity Initiative, which sought to increase awareness of the links between obesity and cancer and to foster research in this area that evaluated the impact of weight loss and increased activity on cancer outcomes. There have been hundreds of observational...
Double-Hit Lymphoma: Many Treatment Strategies, No Standard of Care
"Double-hit lymphoma” represents a challenging malignancy without a standard-of-care treatment, although outcomes for some patients are better than was once believed, according to Jonathon B. Cohen, MD, Assistant Professor of Hematology and Medical Oncology at Emory University, Atlanta. Dr. Cohen...
